Oral tolerance for the treatment of autoimmune diseases

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 341-351

  Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Mucosa; Multiple sclerosis; Suppression; Transforming growth factor

Indexed keywords

AUTOANTIGEN; COLLAGEN TYPE 2; CYTOKINE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; MYELIN; RETINA S ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNITY; DIABETES MELLITUS; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INTESTINE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TARGET ORGAN; THERAPY; UVEITIS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; IMMUNE TOLERANCE; MICE; TREATMENT OUTCOME;

EID: 0031055406     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.341     Document Type: Review

References (75)

1. Wells HG. 1911. Studies on the chemistry of anaphylaxis (III). Experiments with isolated proteins, especially those of the hen's egg. J. Infect. Dis. 8:147-71
2. Chase M. 1946. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med. 61:257-59
3. Mowat AM. 1987. The regulation of immune responses to dietary protein antigens. Immunol. Today 8:93-98
4. Husby S, Mestecky J, Moldoveanu Z, et al. 1994. Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. J. Immunol. 152:4663-70
5. Kerlero de Rosbo N, Milo R, Lees MB, et al. 1993. Reactivity to myelin antigens in multiple sclerosis: peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest. 92:2602-8
6. Zhang J, Markovic S, Raus J, et al. 1993. Increased frequency of IL-2 responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:973-84
7. Weiner HL, Friedman A, Miller A, et al. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:809-37
8. Weiner HL, Mackin GA, Matsui M, et al. 1993. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259:1321-24
9. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. 1993. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-30
10. Sieper J, Kary S, Sörensen H, et al. 1996. Oral type II collagen treatment in early rheumatoid arthritis. Arthritis Rheum. 39: 41-51
11. Barnett ML, Combitchi D, Trentham DE. 1996. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39:623-28
12. Nussenblatt RB, Whitcup SM, De Smet MD, et al. 1996. Intraocular Inflammatory disease (uveitis) and the use of oral tolerance. In Oral Tolerance: Mechanisms and Applications, ed. HL Weiner, LF Mayer, pp. 325-37. New York: NY Acad. Sci.
13. Hohol MJ, Khoury SJ, Cook SL, et al. 1996. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. In Oral Tolerance: Mechanisms and Applications, ed. HL Weiner, LF Mayer, pp. 243-50. New York: NY Acad. Sci.
14. Brandtzaeg P. 1989. Overview of the mucosal immune system. Curr. Top. Microbiol. Immunol. 146:13-28
15. Chen Y, Kuchroo VK, Inobe J-I, et al. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-40
16. Daynes R, Araneo B, Dowell T, et al. 1990. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J. Exp. Med. 171:979-96
17. Kim P-H, Kagnoff MF. 1990. Transforming growth factor-β1 is a costimulatory for IgA production. J. Immunol. 144:3411-46
18. Chin YH, Cai JP, Xu XM. 1992. Transforming growth factor-β1 and IL-4 regulate the adhesiveness of Peyer's patch high endothelial venule cells for lymphocytes. J. Immunol. 148:1106-12
19. Santos LMB, Al-Sabbagh A, Londono A, et al. 1994. Oral tolerance to myelin basic protein induces regulatory TGF-β-secreting T cells in Peyer's patches of SJL mice. Cell. Immunol. 157:439-47
20. Mosmann TR, Sad S. 1996. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17:138-46
21. Miller A, Lider O, Weiner HL. 1991. Antigen-driven bystander suppression following oral administration of antigens. J. Exp. Med. 174:791-98
22. McCarron R, Fallis R, McFarlin D. 1990. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephlomyelitis. J. Neuroimmunol. 29: 73-79
23. Lehmann P, Forsthuber T, Miller A, et al. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155
24. Cross AH, Tuohy VK, Raine CS. 1993. Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination. Cell. Immunol. 146: 261-70
25. Kaufman DL, Clare-Salzier M, Tian J, et al. 1993. Spontaneous loss of T cell tolerance to glutamate decarboxylase in murine insulin-dependent diabetes. Nature 366:769-72
26. Tisch R, Yang X-D, Singer SM, et al. 1993. Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice. Nature 366:72-75
27. Harrison LC. 1992. Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited. Immunol. Today 13:348-52
28. Al-Sabbagh A, Miller A, Santos LMB, et al. 1994. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur. J. Immunol. 24:2104-9
29. Zhang JZ, Lee CSY, Lider O, et al. 1990. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J. Immunol. 145:2489-93
30. Yoshino S, Quattrocchi E, Weiner HL. 1995. Oral administration of type II collagen suppresses antigen-induced arthritis in lewis rats. Arthritis Rheum. 38:1092-96
31. von Herrath M, Dyrberg T, Oldstone MBA. 1996. Oral insulin treatment suppresses virus-induced antigen-specific destruction of β cells and prevents autoimmune diabetes in transgenic mice. J. Clin. Invest. 98(6): 1324-31
32. Bitar D, Whitacre CC. 1988. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol. 112:364-70
33. Whitacre CC, Gienapp IE, Orosz CG, et al. 1991. Oral tolerance in experimental autoimmune encephalomyelits. III. Evidence for clonal anergy. J. Immunol. 147:2155-63
34. Javed NH, Gienapp I, Cox K, et al. 1995. Exquisite specificity of oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 155:1599-605
35. Higgins P, Weiner HL. 1988. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 140:440-45
36. Lider O, Santos LMB, Lee CSY, et al. 1989. Suppression of experimental allergic encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+T lymphocytes. J. Immunol. 142:748-52
37. Miller A, Zhang ZJ, Sobel RA, et al. 1993. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral versus intravenous tolerization. J. Neuroimmunol. 46:73-82
38. Miller A, Al-Sabbagh A, Santos L, et al. 1993. Epitopes of myelin basic protein that trigger TGF-β release following oral tolerization are distinct from encephalitogenic epitopes and mediate epitope driven bystander suppression. J. Immunol. 151: 7307-15
39. Khoury SJ, Hancock WW, Weiner HL. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis as associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-64
40. Brod SA, Al-Sabbagh A, Sobel RA, et al. 1991. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens. IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. Ann. Neurol. 29: 615-22
41. Chen Y, Inobe J-I, Kuchroo VK, et al. 1996. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc. Natl. Acad. Sci. USA 93: 388-91
42. Metzler B, Wrath DC. 1993. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol 5:1159-65
43. Thompson HSG, Staines NA. 1986. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. 64:581-86
44. Nagler-Anderson C, Bober LA, Robinson ME, et al. 1986. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. USA 83:7443-46
45. Thompson HSG, Harper N, Bevan DJ, et al. 1993. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 16:189-99
46. Thompson SJ, Thompson HSG, Harper N, et al. 1993. Prevention of pristine-induced arthritis by the oral administration of type II collagen. Immunology 79:152-57
47. Yoshino S. 1995. Antigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunization. Cell. Immunol. 163:55-58
48. Khare SD, Krco CJ, Griffiths MM, et al. 1995. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J. Immunol. 155:3653-59
49. Staines NA, Harper N, Ward FJ, et al. 1996. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103:368-75
50. Nussenblatt RB, Caspi RR, Mahdi R, et al. 1990. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J. Immunol. 144:1689-95
51. Thurau SR, Chan CC, Suh E, et al. 1991. Induction of oral tolerance to S-antigen induced experimental autoimmune uveitis by a uveitogenic 20mer peptide. J. Autoimmun. 4:507-16
52. Singh VK, Kalra HK, Yamaki K, et al. 1992. Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment are a cross-reactive homologous peptide. Cell. Immunol. 139:81-90
53. Vrabec TR, Gregerson DS, Dua HS, et al. 1992. Inhibition of experimental autoimmune uveoretinitis by oral administration of s-antigen and synthetic peptides. Autoimmunity 12:175-84
54. Gregerson DS, Obritsch WF, Donoso LA. 1993. Oral tolerance in experimental autoimmune uveoretinitis: distinct mechanisms of resistance are induced by low versus high dose feeding protocols. J. Immunol. 151:5751-61
55. Rizzo LV, Miller-Rivero NE, Chan C-C, et al. 1994. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J. Clin. Invest. 94: 1668-72
56. Wildner G, Thurau SR. 1995. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Eur. J. Immunol. 25:1292-97
57. Ma C-G, Zhang G-X, Xiao B-G, et al. 1995. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:51-60
58. Wang Z-Y, Qiao J, Link H. 1993. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44: 209-14
59. Wang ZY, Qiao J, Melms A, et al. 1993. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 152:394-404
60. Okumura S, McIntosh K, Drachman DB. 1994. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann. Neurol. 36:704-13
61. Wang Z-Y, Link H, Ljungdahl Å, et al. 1994. Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 157:353-68
62. Wang Z-Y, Huang J, Olsson T, et al. 1995. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J Neurol. Sci. 128:167-74
63. Zhang JA, Davidson L, Eisenbarth G, et al. 1991. Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88: 10252-56
64. Bergerot J, Fabien N, Maguer V, et al. 1994. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J. Autoimmun. 7:655-63
65. Hancock WW, Polanski M, Zhang ZJ, et al. 1995. Suppression of insulitis in NOD mice by oral insulin administration is associated with selective expression of IL-4, IL-10, TGF-β and prostaglandin-E. Am. J. Pathol. 147:1193-99
66. Daniel D, Wegmann DR. 1996. Protection of nonobese diabetic mice from diabetics by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 93:956-60
67. Tian J, Atkinson MA, Clare-Salzler M, et al. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1561-67
68. Sayegh MH, Zhang ZJ, Hancock WW, et al. 1992. Down-regulation of the immune response to histocompatibility antigen and prevention of sensitization by skin allografts by orally administered alloantigen. Transplantation 53:163-66
69. Sayegh MH, Khoury SJ, Hancock WH, et al. 1992. Induction of immunity and oral tolerance with polymorphic class II major histocompatability complex allopeptides in the rat. Proc. Natl. Acad. Sci. USAs, USA 89:7762-66
70. Hancock W, Sayegh M, Kwok C, et al. 1993. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 55:1112-18
71. Peterson KE, Braley-Mullen H. 1995. Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell. Immunol. 166:123-30
72. Guimaraes VC, Quintans J, Fisfalen M-E, et al. 1995. Suppression of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology 136: 3353-59
73. Lowney ED. 1968. Immunologic unresponsiveness to a contact sensitizer in man. J. Invest. Dermatol. 51:411-17
74. Waldo FB, Van Den Wall Bake AWL, Mestecky J, et al. 1994. Suppression of the immune response by nasal immunization. Clin. Immunol. Immunopathol. 72:30-34
75. Fukaura H, Kent SC, Pietrusewicz MJ, et al. 1996. Induction of circulating myelin basic protein and proteolipid protein specific TGF-β1 secreting T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98:70-77